Multifunctional stimuli-responsive nanoparticles for targeted delivery of small and macromolecular therapeutics

Targeted Delivery of Small and Macromolecular Drugs

Volumn , Issue , 2010, Pages 555-586

  Ganta, Srinivas ^a   Iyer, Arun ^b   Amiji, Mansoor ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84937390560     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/9781420087734     Document Type: Chapter

References (175)

1. Alonso MJ. Nanomedicines for overcoming biological barriers. Biomedicine & Pharmacotherapy. 2004; 58(3): 168-172.
2. Belting M, Sandgren S, Wittrup A. Nuclear delivery of macromolecules: Barriers and carriers. Advanced Drug Delivery Reviews. 2005; 57(4): 505-527.
3. Yih TC, Al-Fandi M. Engineered nanoparticles as precise drug delivery systems. Journal of Cellular Biochemistry. 2006; 97(6): 1184-1190.
4. Garnett MC. Targeted drug conjugates: Principles and progress. Advanced Drug Delivery Reviews. 2001; 53(2): 171-216.
5. Vasir JK, Reddy MK, Labhasetwar VD. Nanosystems in drug targeting: Opportunities and challenges. Current Nanoscience. 2005; 1: 47-64.
6. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: A review. Journal of Controlled Release. 2000; 65(1-2):271-284.
7. Torchilin VP. Recent approaches to intracellular delivery of drugs and DNA and organelle targeting. Annual Review of Biomedical Engineering. 2006; 8(1): 343-375.
8. Ganta S, Devalapally H, Shahiwala A, Amiji M. A review of stimuli-responsive nanocarriers for drug and gene delivery. Journal of Controlled Release. 2008; 126: 187-204.
9. Couvreur P, Vauthier C. Nanotechnology: Intelligent design to treat complex disease. Pharmaceutical Research. 2006; 23(7): 1417-1450.
10. Jain RK. Vascular and interstitial barriers to delivery of therapeutic agents in tumors. Cancer and Metastasis Reviews. 1990; 9(3): 253-266.
11. Maeda H, Matsumura Y. Tumoritropic and lymphotropic principles of macromolecular drugs. Critical Reviews in Therapeutic Drug Carrier Systems. 1989; 6(3): 193-210.
12. Seymour LW. Passive tumor targeting of soluble macromolecules and drug conjugates. Critical Reviews in Therapeutic Drug Carrier Systems. 1992; 9(2): 135-187.
13. Yuan F. Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Research. 1994; 54(13): 3352-3356.
14. Baban DF, Seymour LW. Control of tumour vascular permeability. Advanced Drug Delivery Reviews. 1998; 34(1): 109-119.
15. Brannon-Peppas L, Blanchette JO. Nanoparticle and targeted systems for cancer therapy. Advanced Drug Delivery Reviews. 2004; 56(11): 1649-1659.
16. Torchilin VP. Drug targeting. European Journal of Pharmaceutical Sciences. 2000; 11: 81-91.
17. Gabizon AA. Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes. Cancer Research. 1992; 52(4): 891-896.
18. Allen TM, Cullis PR. Drug delivery systems: Entering the mainstream. Science. 2004; 303(5665):1818.
19. Davis SS. Biomédical applications of nanotechnology-Implications for drug targeting and gene therapy. Trends in Biotechnology. 1997; 15(6): 217-224.
20. Johns P, Courts A. Relationship between collagen and gelatin. In AGW, Courts A, eds., The Science and Technology of Gelatin, London, U.K.: Academic Press; 1977.
21. Kommareddy S, Tiwari SB, Amiji MM. Long-circulating polymeric nanovectors for tumor-selective gene delivery. Technology in Cancer Research and Treatment. 2005; 4(6): 615-625.
22. Kaul G, Amiji M. Tumor-targeted gene delivery using poly (ethylene glycol)-modified gelatin nanoparticles:In vitro and in vivo studies. Pharmaceutical Research. 2005; 22(6):951.
23. Kaul G, Amiji M. Cellular interactions and in vitro DNA transfection studies with poly (ethylene glycol)- modified gelatin nanoparticles. Journal of Pharmaceutical Sciences. 2005; 94(1): 184-198.
24. Marcucci F, Lefoulon F. Active targeting with particulate drug carriers in tumor therapy: Fundamentals and recent progress. Drug Discovery Today. 2004; 9(5): 219-228.
25. Ríhová B. Receptor-mediated targeted drug or toxin delivery. Advanced Drug Delivery Reviews. 1998; 29(3): 273-289.
26. Farokhzad OC, Karp JM, Langer R. Nanoparticle-aptamer bioconjugates for cancer targeting. Expert Opinion on Drug Delivery. 2006; 3(3): 311-324.
27. Chung NS, Wasan KM. Potential role of the low-density lipoprotein receptor family as mediators of cellular drug uptake. Advanced Drug Delivery Reviews. 2004; 56(9): 1315-1334.
28. Rensen PCN, Schiffelers RM, Versluis AJ, Bijsterbosch MK, Van Kuijk-Meuwissen MEMJ, Van Berkel TJC. Human recombinant apolipoprotein E-enriched liposomes can mimic low-density lipoproteins as carriers for the site-specific delivery of antitumor agents. Molecular Pharmacology. 1997 September 1, 1997; 52(3):445-455.
29. Amin K, Ng KY, Brown CS, Bruno MS, Heath TD. LDL induced association of anionic liposomes with cells and delivery of contents as shown by the increase in potency of liposome dependent drugs. Pharmaceutical Research. 2001; 18(7): 914-921.
30. Kirpotin DB, Drummond DC, Shao Y, Shalaby MR, Hong K, Nielsen UB et al. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Research. 2006 July 1, 2006; 66(13):6732-6740.
31. Sahoo SK, Labhasetwar V. Enhanced antiproliferative activity of transferrin-conjugated paclitaxelloaded nanoparticles is mediated via sustained intracellular drug retention. Molecular Pharmaceutics. 2005; 2(5): 373-383.
32. Blessing T, Kursa M, Holzhauser R, Kircheis R, Wagner E. Different strategies for formation of PEGylated EGF-conjugated PEI/DNA complexes for targeted gene delivery. Bioconjugate Chemistry. 2001; 12(4): 529-537.
33. Leiden JM. Gene therapy-promise, pitfalls, and prognosis. The New England Journal of Medicine. 1995; 333(13): 871-873.
34. Oishi M, Nagasaki Y. Synthesis, characterization, and biomedical applications of core-shell-type stimuliresponsive nanogels-Nanogel composed of poly [2-(N, N-diethylamino) ethyl methacrylate] core and PEG tethered chains. Reactive and Functional Polymers. 2007; 67(11): 1311-1329.
35. Panyam J, Labhasetwar V. Targeting intracellular targets. Current Drug Delivery. 2004; 1: 235-247.
36. Kichler A, Leborgne C, Coeytaux E, Danos O. Polyethylenimine-mediated gene delivery: A mechanistic study. Journal of Gene Medicine. 2001; 3(2): 135-144.
37. Ogris M, Wagner E. Targeting tumors with non-viral gene delivery systems. Drug Discovery Today. 2002; 7(8): 479-485.
38. Järver P, Langel Ü. The use of cell-penetrating peptides as a tool for gene regulation. Drug Discovery Today. 2004; 9(9): 395-402.
39. Snyder EL, Dowdy SF. Protein/peptide transduction domains: Potential to deliver large DNA molecules into cells. Current Opinion in Molecular Therapeutics. 2001; 3(2): 147-152.
40. Torchilin VP, Rammohan R, Weissig V, Levchenko TS. TAT peptide on the surface of liposomes affords their efficient intracellular delivery even at low temperature and in the presence of metabolic inhibitors. Proceedings of the National Academy of Sciences. 2001; 98(15):8786.
41. Weissig V, Torchilin VP. Drug and DNA delivery to mitochondria. Advanced Drug Delivery Reviews. 2001; 49(1-2):1-2.
42. Ferrari M. Cancer nanotechnology: Opportunities and challenges. Nature Reviews Cancer. 2005; 5(3): 161-171.
43. Jabr-Milane LS, van Vlerken LE, Yadav S, Amiji MM. Multi-functional nanocarriers to overcome tumor drug resistance. Cancer Treatment Reviews. 2008; 34: 592-602.
44. Levy L, Sahoo Y, Kim KS, Bergey EJ, Prasad PN. Nanochemistry: Synthesis and characterization of multifunctional nanoclinics for biological applications. Chemistry of Materials. 2002; 14(9): 3715-3721.
45. Feldherr CM, Akin D. The permeability of the nuclear envelope in dividing and nondividing cell cultures. The Journal of Cell Biology. 1990; 111(1): 1-8.
46. Hogemann D, Ntziachristos V, Josephson L, Weissleder R. High throughput magnetic resonance imaging for evaluating targeted nanoparticle probes. Bioconjugate Chemistry. 2002; 13(1): 116-121.
47. Nasongkla N, Bey E, Ren J, Ai H, Khemtong C, Guthi JS et al. Multifunctional polymeric micelles as cancer-targeted, MRI-ultrasensitive drug delivery systems. Nano Letters. 2006; 6(11): 2427-2430.
48. Gerweck LE. Cellular pH gradient in tumor versus normal tissue: Potential exploitation for the treatment of cancer. Cancer Research. 1996; 56(6): 1194-1198.
49. Hunt CA, MacGregor RD, Siegel RA. Engineering targeted in vivo drug delivery. I. The physiological and physicochemical principles governing opportunities and limitations. Pharmaceutical Research. 1986; 3(6): 333-344.
50. Lee ES, Gao Z, Bae YH. Recent progress in tumor pH targeting nanotechnology. Journal of Controlled Release. 2008; 132(3): 164-710.
51. You J-O, Auguste DT. Feedback-regulated paclitaxel delivery based on poly(N, N-dimethylaminoethyl methacrylate-co-2-hydroxyethyl methacrylate) nanoparticles. Biomaterials. 2008; 29(12): 1950-1957.
52. Torchilin V. Multifunctional and stimuli-sensitive pharmaceutical nanocarriers. European Journal of Pharmaceutics and Biopharmaceutics 2009; 71(3): 431-444.
53. Fan L, Wu H, Zhang H, Li F, Yang T-h, Gu C-h et al. Novel super pH-sensitive nanoparticles responsive to tumor extracellular pH. Carbohydrate Polymers. 2008; 73(3): 390-400.
54. Stover TC, Kim YS, Lowe TL, Kester M. Thermoresponsive and biodegradable linear-dendritic nanoparticles for targeted and sustained release of a pro-apoptotic drug. Biomaterials. 2008; 29(3): 359-369.
55. Gal D, MacDonald PC, Porter JC, Simpson ER. Cholesterol metabolism in cancer cells in monolayer culture. III. Low-density lipoprotein metabolism. International Journal of Cancer. 1981; 28(3): 315-319.
56. Wike-Hooley JL, Haveman J, Reinhold HS. The relevance of tumour pH to the treatment of malignant disease. Radiotherapy and Oncology. 1984; 2(4): 343-366.
57. Vaupel P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors:A review. Cancer Research. 1989; 49(23): 6449-6465.
58. Dewhirst MW, Prosnitz L, Thrall D, Prescott D, Clegg S, Charles C et al. Hyperthermic treatment of malignant diseases: Current status and a view toward the future. Seminars in Oncology. 1997; 24(6): 616-625.
59. Engin K. Biological rationale and clinical experience with hyperthermia. Controlled Clinical Trials. 1996; 17(4): 316-342.
60. Gupta AK, Naregalkar RR, Vaidya VD, Gupta M. Recent advances on surface engineering of magnetic iron oxide nanoparticles and their biomedical applications. Nanomedicine. 2007; 2(1): 23-39.
61. Ahmed M, Lukyanov AN, Torchilin V, Tournier H, Schneider AN, Goldberg SN. Combined radiofrequency ablation and adjuvant liposomal chemotherapy: Effect of chemotherapeutic agent, nanoparticle size, and circulation time. Journal of Vascular and Interventional Radiology. 2005; 16(10): 1365-1371.
62. Meyer DE, Shin BC, Kong GA, Dewhirst MW, Chilkoti A. Drug targeting using thermally responsive polymers and local hyperthermia. Journal of Controlled Release. 2001; 74(1-3):213-224.
63. Ponce AM, Vujaskovic Z, Yuan F, Needham D, Dewhirst MW. Hyperthermia mediated liposomal drug delivery. International Journal of Hyperthermia. 2006; 22(3): 205-213.
64. Saito G, Swanson JA, Lee KD. Drug delivery strategy utilizing conjugation via reversible disulfide linkages:Role and site of cellular reducing activities. Advanced Drug Delivery Reviews. 2003; 55(2): 199-215.
65. Noss EH, Pai RK, Sellati TJ, Radolf JD, Belisle J, Golenbock DT et al. Toll-like receptor 2-dependent inhibition of macrophage class II MHC expression and antigen processing by 19-kDa lipoprotein of Mycobacterium tuberculosis 1. The Journal of Immunology. 2001; 167(2): 910-918.
66. Kawai N, Ito A, Nakahara Y, Futakuchi M, Shirai T, Honda H et al. Anticancer effect of hyperthermia on prostate cancer mediated by magnetite cationic liposomes and immune-response induction in transplanted syngeneic rats. The Prostate. 2005; 64: 373-381.
67. Anderson SA, Glod J, Arbab AS, Noel M, Ashari P, Fine HA et al. Noninvasive MR imaging of magnetically labeled stem cells to directly identify neovasculature in a glioma model. Blood. 2005; 105(1):420.
68. Pitt WG, Husseini GA, Staples BJ. Ultrasonic drug delivery-A general review. Expert Opinion on Drug Delivery. 2004; 1(1):37.
69. Pissuwan D, Valenzuela SM, Cortie MB. Therapeutic possibilities of plasmonically heated gold nanoparticles. Trends in Biotechnology. 2006; 24(2): 62-67.
70. Paasonen L, Laaksonen T, Johans C, Yliperttula M, Kontturi K, Urtti A. Gold nanoparticles enable selective light-induced contents release from liposomes. Journal of Controlled Release. 2007; 122(1): 86-93.
71. Soppimath KS, Tan DCW, Yang YY. pH-triggered thermally responsive polymer core-shell nanoparticles for drug delivery. Advanced Materials (Weinheim). 2005; 17(3): 318-323.
72. Bae Y, Nishiyama N, Kataoka K. In vivo antitumor activity of the folate-conjugated pH-sensitive polymeric micelle selectively releasing adriamycin in the intracellular acidic compartments. Bioconjugate Chemistry. 2007; 18: 1131-1139.
73. Shenoy D, Little S, Langer R, Amiji M. Poly (ethylene oxide)-modified poly(ß-amino ester) nanoparticles as a pH-sensitive system for tumor-targeted delivery of hydrophobic drugs: Part I. In vitro evaluations. Molecular Pharmaceutics. 2005; 2(5):357.
74. Shenoy DB, Amiji MM. Poly (ethylene oxide)-modified poly (epsilon-caprolactone) nanoparticles for targeted delivery of tamoxifen in breast cancer. International Journal of Pharmaceutics. 2005; 293(1-2):261-270.
75. Devalapally H, Shenoy D, Little S, Langer R, Amiji M. Poly (ethylene oxide)-modified poly (beta-amino ester) nanoparticles as a pH-sensitive system for tumor-targeted delivery of hydrophobic drugs: Part 3. Therapeutic efficacy and safety studies in ovarian cancer xenograft model. Cancer Chemotherapy and Pharmacology. 2007; 59(4): 477-484.
76. Shenoy D, Little S, Langer R, Amiji M. Poly(ethylene oxide)-modified poly(β-amino ester) nanoparticles as a pH-sensitive system for tumor-targeted delivery of hydrophobic drugs: Part 2. In vivo distribution and tumor localization studies. Pharmaceutical Research. 2005; 22(12): 2107-2114.
77. Na K, Seong Lee E, Bae YH. Adriamycin loaded pullulan acetate/sulfonamide conjugate nanoparticles responding to tumor pH: pH-dependent cell interaction, internalization and cytotoxicity in vitro. Journal of Controlled Release. 2003; 87(1-3):3-13.
78. Stayton PS, El-Sayed MEH, Murthy N, Bulmus V, Lackey C, Cheung C et al. ‘Smart’delivery systems for biomolecular therapeutics. Orthodontics & Craniofacial Research. 2005; 8(3): 219-225.
79. Murthy N, Campbell J, Fausto N, Hoffman AS, Stayton PS. Design and synthesis of pH-responsive polymeric carriers that target uptake and enhance the intracellular delivery of oligonucleotides. Journal of Controlled Release. 2003; 89(3): 365-374.
80. Bulmus V, Woodward M, Lin L, Murthy N, Stayton P, Hoffman A. A new pH-responsive and glutathionereactive, endosomal membrane-disruptive polymeric carrier for intracellular delivery of biomolecular drugs. Journal of Controlled Release. 2003; 93(2): 105-120.
81. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nature Reviews Drug Discovery. 2005; 4(2): 145-160.
82. Simões S, Moreira JN, Fonseca C, Düzgünes N, Pedroso de Lima MC. On the formulation of pH-sensitive liposomes with long circulation times. Advanced Drug Delivery Reviews. 2004; 56(7): 947-965.
83. Kakudo T, Chaki S, Futaki S, Nakase I, Akaji K, Kawakami T et al. Transferrin-modified liposomes equipped with a pH-sensitive fusogenic peptide: An artificial viral-like delivery system. Biochemistry. 2004; 43(19): 5618-5628.
84. Roux E, Passirani C, Scheffold S, Benoit JP, Leroux JC. Serum-stable and long-circulating, PEGylated, pH-sensitive liposomes. Journal of Controlled Release. 2004; 94(2-3):447-451.
85. Wang CY, Huang L. Highly efficient DNA delivery mediated by pH-sensitive immunoliposomes. Biochemistry. 1989; 28(24): 9508-9514.
86. Litzinger DC, Huang L. Phosphatodylethanolamine liposomes: Drug delivery, gene transfer and immunodiagnostic applications. BBA-Reviews on Biomembranes. 1992; 1113(2): 201-227.
87. Connor J. pH-sensitive immunoliposomes as an efficient and target-specific carrier for antitumor drugs. Cancer Research. 1986; 46(7): 3431-3435.
88. Couvreu P, Fattal E, Malvy C, Dubernet C. pH-sensitive liposomes: An intelligent system for the delivery of antisense oligonucleotides. Journal of Liposome Research. 1997; 7(1): 1-18.
89. Leroux JC, Roux E, Le Garrec D, Hong K, Drummond DC. N-isopropylacrylamide copolymers for the preparation of pH-sensitive liposomes and polymeric micelles. Journal of Controlled Release. 2001; 72(1-3):71-84.
90. Ellens H, Bentz J, Szoka FC. pH-Induced destabilization of phosphatidylethanolamine-containing liposomes:Role of bilayer contact. Biochemistry. 1984; 23(7): 1532-1538.
91. Ishida T, Kirchmeier MJ, Moase EH, Zalipsky S, Allen TM. Targeted delivery and triggered release of liposomal doxorubicin enhances cytotoxicity against human B lymphoma cells. BBA-Biomembranes. 2001; 1515(2): 144-158.
92. Lee RJ, Wang S, Turk MJ, Low PS. The effects of pH and intraliposomal buffer strength on the rate of liposome content release and intracellular drug delivery. Bioscience Reports. 1998; 18(2): 69-78.
93. Kataoka K, Harada A, Nagasaki Y. Block copolymer micelles for drug delivery: Design, characterization and biological significance. Advanced Drug Delivery Reviews. 2001; 47(1): 113-131.
94. Kwon GS, Okano T. Polymeric micelles as new drug carriers. Advanced Drug Delivery Reviews. 1996; 21(2): 107-116.
95. Gillies ER, Frechet JMJ. Development of acid-sensitive copolymer micelles for drug delivery. Pure and Applied Chemistry. 2004; 76: 1295-1308.
96. Shim WS, Kim SW, Choi EK, Park HJ, Kim JS, Lee DS. Novel pH sensitive block copolymer micelles for solvent free drug loading. Macromolecular Bioscience. 2006; 6(2):179.
97. Lee ES, Shin HJ, Na K, Bae YH. Poly (l-histidine)-PEG block copolymer micelles and pH-induced destabilization. Journal of Controlled Release. 2003; 90(3): 363-374.
98. Bae Y, Nishiyama N, Fukushima S, Koyama H, Yasuhiro M, Kataoka K. Preparation and biological characterization of polymeric micelle drug carriers with intracellular pH-triggered drug release property:Tumor permeability, controlled subcellular drug distribution, and enhanced in vivo antitumor efficacy. Bioconjugate Chemistry. 2005; 16(1): 122-130.
99. Liu S, Armes SP. Synthesis and aqueous solution behavior of a pH-responsive schizophrenic diblock copolymer. Langmuir. 2003; 19(10): 4432-4438.
100. Bütün V, Armes SP, Billingham NC, Tuzar Z, Rankin A, Eastoe J et al. The remarkable ‘flip-flop’selfassembly of a diblock copolymer in aqueous solution. Macromolecules. 2001; 34(5): 1503-1511.
101. Yoshida R, Uchida K, Kaneko Y, Sakai K, Kikuchi A, Sakurai Y et al. Comb-type grafted hydrogels with rapid de-swelling response to temperature changes. Nature. 1995; 374(6519): 240-242.
102. Beltran S, Baker JP, Hooper HH, Blanch HW, Prausnitz JM. Swelling equilibria for weakly ionizable, temperature-sensitive hydrogels. Macromolecules. 1991; 24(2): 549-551.
103. Taillefer J, Jones MC, Brasseur N, Van Lier JE, Leroux JC. Preparation and characterization of pH-responsive polymeric micelles for the delivery of photosensitizing anticancer drugs. Journal of Pharmaceutical Sciences. 2000; 89(1): 52-62.
104. Le Garrec D, Taillefer J, Van Lier JE, Lenaerts V. Optimizing pH-responsive polymeric micelles for drug delivery in a cancer photodynamic therapy model. Journal of Drug Targeting. 2002; 10(5): 429-437.
105. Hsiue GH, Wang CH, Lo CL, Li JP, Yang JL. Environmental-sensitive micelles based on poly (2-ethyl-2-oxazoline)-b-poly (l-lactide) diblock copolymer for application in drug delivery. International Journal of Pharmaceutics. 2006; 317(1): 69-75.
106. Bajpai AK, Shukla SK, Bhanu S, Kankane S. Responsive polymers in controlled drug delivery. Progress in Polymer Science. 2008; 33(11): 1088-1118.
107. Chiappetta DA, Sosnik A. Poly(ethylene oxide)-poly(propylene oxide) block copolymer micelles as drug delivery agents: Improved hydrosolubility, stability and bioavailability of drugs. European Journal of Pharmaceutics and Biopharmaceutics. 2007; 66(3): 303-317.
108. Harada A, Kataoka K. Supramolecular assemblies of block copolymers in aqueous media as nanocontainers relevant to biological applications. Progress in Polymer Science. 2006; 31(11): 949-982.
109. Lee ES, Na K, Bae YH. Super pH-sensitive multifunctional polymeric micelle. Nano Letters. 2005; 5(2): 325-329.
110. Tomalia DIA, Dvornic PR. What promise for dendrimers. Nature. 1994; 372(6507): 617-618.
111. Esfand R, Tomalia DA. Poly (amidoamine)(PAMAM) dendrimers: From biomimicry to drug delivery and biomedical applications. Drug Discovery Today. 2001; 6(8): 427-436.
112. Ihre HR, De Jesus OLP, Szoka FC, Frechet JMJ. Polyester dendritic systems for drug delivery applications:Design, synthesis, and characterization. Bioconjugate Chemistry. 2002; 13(3): 443-452.
113. Gillies ER, Jonsson TB, Frechet JMJ. Stimuli-responsive supramolecular assemblies of linear-dendritic copolymers. Journal-American Chemical Society. 2004; 126(38): 11936-11943.
114. Hui H, Xiao-dong F, Zhong-lin C. Thermo- and pH-sensitive dendrimer derivatives with a shell of poly(N, N-dimethylaminoethyl methacrylate) and study of their controlled drug release behavior. Polymer. 2005; 46(22): 9514-9522.
115. Kono K, Kojima C, Hayashi N, Nishisaka E, Kiura K, Watarai S et al. Preparation and cytotoxic activity of poly(ethylene glycol)-modified poly(amidoamine) dendrimers bearing adriamycin. Biomaterials. 2008; 29(11): 1664-1675.
116. Kim SY, Ha JC, Lee YM. Poly (ethylene oxide)-poly (propylene oxide)-poly (ethylene oxide)/poly (epsilon- caprolactone)(PCL) amphiphilic block copolymeric nanospheres II. Thermo-responsive drug release behaviors. Journal of Controlled Release. 2000; 65(3): 345-358.
117. Bae KH, Choi SH, Park SY, Lee Y, Park TG. Thermosensitive pluronic micelles stabilized by shell crosslinking with gold nanoparticles. Langmuir. 2006; 22(14): 6380-6384.
118. Rijcken CJF, Soga O, Hennink WE, Nostrum CF. Triggered destabilisation of polymeric micelles and vesicles by changing polymers polarity: An attractive tool for drug delivery. Journal of Controlled Release. 2007; 120(3): 131-148.
119. Molineux G. Pegylation: Engineering improved pharmaceuticals for enhanced therapy. Cancer Treatment Reviews. 2002; 28: 13-16.
120. Chung JE, Yokoyama M, Okano T. Inner core segment design for drug delivery control of thermo- responsive polymeric micelles. Journal of Controlled Release. 2000; 65(1-2):93-103.
121. Yokoyama M. Gene delivery using temperature-responsive polymeric carriers. Drug Discovery Today. 2002; 7(7): 426-432.
122. Türk M, Dinçer S, Yulug IG, Piskin E. In vitro transfection of HeLa cells with temperature sensitive polycationic copolymers. Journal of Controlled Release. 2004; 96(2): 325-340.
123. Turk M, Dincer S, Piskin E. Smart and cationic poly (NIPA)/PEI block copolymers as non-viral vectors:In vitro and in vivo transfection studies. Journal of Tissue Engineering and Regenerative Medicine. 2007; 5: 377-388.
124. Dincer S, Turk M, Piskin E. Intelligent polymers as nonviral vectors. Gene Therapy. 2005; 12(1):S139-S145.
125. Piskin E. Stimuli-responsive polymers in gene delivery. Expert Reviews of Medical Devices. 2005; 2(4): 501-509.
126. Yatvin MB, Weinstein JN, Dennis WH, Blumenthal R. Design of liposomes for enhanced local release of drugs by hyperthermia. Science. 1978; 202(4374): 1290-1293.
127. Chen Q, Tong S, Dewhirst MW, Yuan F. Targeting tumor microvessels using doxorubicin encapsulated in a novel thermosensitive liposome. Molecular Cancer Therapeutics. 2004; 3(10): 1311-1317.
128. Kono K, Nakai R, Morimoto K, Takagishi T. Thermosensitive polymer-modified liposomes that release contents around physiological temperature. BBA-Biomembranes. 1999; 1416(1-2):239-250.
129. Kono K, Nakai R, Morimoto K, Takagishi T. Temperature-dependent interaction of thermo-sensitive polymer-modified liposomes with CV1 cells. FEBS Letters. 1999; 456(2): 306-310.
130. Kono K, Yoshino K, Takagishi T. Effect of poly (ethylene glycol) grafts on temperature-sensitivity of thermosensitive polymer-modified liposomes. Journal of Controlled Release. 2002; 80(1-3):321-332.
131. Han HD, Shin BC, Choi HS. Doxorubicin-encapsulated thermosensitive liposomes modified with poly (N-isopropylacrylamide-co-acrylamide): Drug release behavior and stability in the presence of serum. European Journal of Pharmaceutics and Biopharmaceutics. 2006; 62(1): 110-116.
132. Kono K. Thermosensitive polymer-modified liposomes. Advanced Drug Delivery Reviews. 2001; 53(3): 307-319.
133. Ward CM, Read ML, Seymour LW. Systemic circulation of poly (l-lysine)/DNA vectors is influenced by polycation molecular weight and type of DNA: Differential circulation in mice and rats and the implications for human gene therapy. Blood. 2001; 97(8):2221.
134. Cavallaro G, Campisi M, Licciardi M, Ogris M, Giammona G. Reversibly stable thiopolyplexes for intracellular delivery of genes. Journal of Controlled Release. 2006; 115(3): 322-334.
135. Voutsadakis IA. Gemtuzumab ozogamicin (CMA-676, Mylotarg) for the treatment of CD33+ acute myeloid leukemia. Anticancer Drugs. 2002; 13: 685-692.
136. Kommareddy S, Amiji M. Preparation and evaluation of thiol-modified gelatin nanoparticles for intracellular DNA delivery in response to glutathione. Bioconjugate Chemistry. 2005; 16(6): 1423-1432.
137. Kommareddy S, Amiji M. Poly (ethylene glycol)-modified thiolated gelatin nanoparticles for glutathione- responsive intracellular DNA delivery. Nanomedicine: Nanotechnology, Biology, and Medicine. 2007; 3(1): 32-42.
138. Kommareddy S, Amiji M. Antiangiogenic gene therapy with systemically administered sFlt-1 plasmid DNA in engineered gelatin-based nanovectors. Cancer Gene Therapy. 2007; 14(5):488.
139. Godbey WT, Wu KK, Mikos AG. Poly(ethylenimine) and its role in gene delivery. Journal of Controlled Release. 1999; 60(2-3):149-160.
140. Neu M, Germershaus O, Mao S, Voigt KH, Behe M, Kissel T. Crosslinked nanocarriers based upon poly (ethylene imine) for systemic plasmid delivery: In vitro characterization and in vivo studies in mice. Journal of Controlled Release. 2007; 118(3): 370-380.
141. Carlisle RC, Etrych T, Briggs SS, Preece JA, Ulbrich K, Seymour LW. Polymer-coated polyethylenimine/DNA complexes designed for triggered activation by intracellular reduction. Journal of Gene Medicine. 2004; 6(3): 337-344.
142. Schmitz T, Bravo-Osuna I, Vauthier C, Ponchel G, Loretz B, Bernkop-Schnürch A. Development and in vitro evaluation of a thiomer-based nanoparticulate gene delivery system. Biomaterials. 2007; 28(3): 524-531.
143. Sun Y-X, Zeng X, Meng Q-F, Zhang X-Z, Cheng S-X, Zhuo R-X. The influence of RGD addition on the gene transfer characteristics of disulfide-containing polyethyleneimine/DNA complexes. Biomaterials. 2008; 29(32): 4356-4365.
144. West KR, Otto S. Reversible covalent chemistry in drug delivery. Current Drug Discovery Technologies. 2005; 2(3):123.
145. Huang Z, Li W, MacKay JA, Szoka FC Jr. Thiocholesterol-based lipids for ordered assembly of bioresponsive gene carriers. Molecular Therapy. 2005; 11: 409-417.
146. Kirpotin D, Hong K, Mullah N, Papahadjopoulos D, Zalipsky S. Liposomes with detachable polymer coating: Destabilization and fusion of dioleoylphosphatidylethanolamine vesicles triggered by cleavage of surface-grafted poly (ethylene glycol). FEBS Letters. 1996; 388(2-3):115-118.
147. Gabizon AA, Tzemach D, Horowitz AT, Shmeeda H, Yeh J, Zalipsky S. Reduced toxicity and superior therapeutic activity of a mitomycin C lipid-based prodrug incorporated in pegylated liposomes. Clinical Cancer Research. 2006; 12(6): 1913-1920.
148. Sun C, Lee JSH, Zhang M. Magnetic nanoparticles in MR imaging and drug delivery. Advanced Drug Delivery Reviews. 2008; 60(11): 1252-1265.
149. Gupta AK, Gupta M. Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials. 2005; 26(18): 3995-4021.
150. Lubbe AS, Bergemann C, Riess H, Schriever F, Reichardt P, Possinger K et al. Clinical experiences with magnetic drug targeting: A phase I study with 4′-epidoxorubicin in 14 patients with advanced solid tumors. Cancer Research. 1996; 56(20): 4686-4693.
151. Alexiou C, Schmid RJ, Jurgons R, Kremer M, Wanner G, Bergemann C et al. Targeting cancer cells:Magnetic nanoparticles as drug carriers. European Biophysics Journal. 2006; 35(5): 446-450.
152. Ito A, Kuga Y, Honda H, Kikkawa H, Horiuchi A, Watanabe Y et al. Magnetite nanoparticle-loaded anti-HER2 immunoliposomes for combination of antibody therapy with hyperthermia. Cancer Letters. 2004; 212(2): 167-175.
153. Dobson J. Gene therapy progress and prospects: Magnetic nanoparticle-based gene delivery. Gene Therapy. 2006; 13: 283-287.
154. Frenkel V. Ultrasound mediated delivery of drugs and genes to solid tumors. Advanced Drug Delivery Reviews. 2008; 60(10): 1193-1208.
155. Rapoport N, Marin A, Christensen DA. Ultrasound-activated drug delivery. Drug Delivery Systems and Sciences. 2002; 2: 37-46.
156. Rapoport N. Physical stimuli-responsive polymeric micelles for anti-cancer drug delivery. Progress in Polymer Science. 2007; 32(8-9):962-990.
157. De Jong WH, Borm PJA. Drug delivery and nanoparticles: Applications and hazards. International Journal of Nanomedicine. 2008; 3(2):133.
158. Colvin VL. The potential environmental impact of engineered nanomaterials. Nature Biotechnology. 2003; 21: 1166-1170.
159. Hunter AC, Moghimi SM. Therapeutic synthetic polymers: A game of Russian roulette? Drug Discovery Today. 2002; 7(19):998-1001.
160. Sayes CM, Liang F, Hudson JL, Mendez J, Guo W, Beach JM et al. Functionalization density dependence of single-walled carbon nanotubes cytotoxicity in vitro. Toxicology Letters. 2006; 161(2): 135-142.
161. Shvedova A, Castranova V, Kisin E, Schwegler-Berry D, Murray A, Gandelsman V et al. Exposure to carbon nanotube material: Assessment of nanotube cytotoxicity using human keratinocyte cells. Journal of Toxicology and Environmental Health, Part A. 2003; 66(20): 1909-1926.
162. Lam KH, Schakenraad JM, Esselbrugge H, Feijen J, Nieuwenhuis P. The effect of phagocytosis of poly(llactic acid) fragments on cellular morphology and viability. Journal of Biomedical Materials Research. 1993; 27(12): 1569-1577.
163. Savic R, Luo LB, Eisenberg A, Maysinger D. Nanocontainers distribute to defined cytoplasmic organelles. Science. 2003; 300: 615-618.
164. Nishiyama N, Koizumi F, Okazaki S, Matsumura Y, Nishio K, Kataoka K. Differential gene expression profile between PC-14 cells treated with free cisplatin and cisplatin-incorporated polymeric micelles. Bioconjugate Chemistry. 2003; 14(2): 449-457.
165. Demoy M, Gibaud S, Andreux JP, Weingarten C, Gouritin B, Couvreur P. Splenic trapping of nanoparticles:Complementary approaches for in situ studies. Pharmaceutical Research. 1997; 14(4): 463-468.
166. Moghimi SM, Hunter AC, Murray JC. Nanomedicine: Current status and future prospects. FASEB Journal. 2005; 19(3): 311-330.
167. Birnbaum DT, Kosmala JD, Henthorn DB, Brannon-Peppas L. Controlled release of ß-estradiol from PLAGA microparticles: The effect of organic phase solvent on encapsulation and release. Journal of Controlled Release. 2000; 65(3): 375-387.
168. Bodmeier R, McGinity JW. Solvent selection in the preparation of poly (dl-lactide) microspheres prepared by the solvent evaporation method. International Journal of Pharmaceutics. 1988; 43(1-2):179-186.
169. Arshady R. Preparation of biodegradable microspheres and microcapsules. II, Polylatides and related polyesters. Journal of Controlled Release. 1991; 17(1): 1-22.
170. Ogawara K-i, Yoshida M, Kubo J-i, Nishikawa M, Takakura Y, Hashida M et al. Mechanisms of hepatic disposition of polystyrene microspheres in rats: Effects of serum depend on the sizes of microspheres. Journal of Controlled Release. 1999; 61(3): 241-250.
171. Kobayashi H, Kawamoto S, Jo SK, Bryant HL, Brechbiel MW, Star RA. Macromolecular MRI contrast agents with small dendrimers: Pharmacokinetic differences between sizes and cores. Bioconjugate Chemistry. 2003; 14(2): 388-394.
172. Pan J, Feng SS. Targeted delivery of paclitaxel using folate-decorated poly (lactide)-vitamin E TPGS nanoparticles. Biomaterials. 2008; 29(17): 2663-2672.
173. Patri A, Dobrovolskaia M, Stern S, McNeil S. Preclinical characterization of engineered nanoparticles intended for cancer therapeutics. In MM Amiji, ed., Nanotechnology for Cancer Therapy, Boca Raton, FL: CRC Press/Taylor & Francis; 2006.
174. Anderson DG, Levenberg S, Langer R. Nanoliter-scale synthesis of arrayed biomaterials and application to human embryonic stem cells. Nature Biotechnology. 2004 Jul;22(7):863-866.
175. United States. Food and Drug Administration CDER/CBER Guidance for industry ICH S6: Preclinical safety evaluation of biotechnology-derived pharmaceuticals 1997.